Hemgenix is a one-time gene therapy for adults with hemophilia B, a condition where blood doesn't clot well. It is given once as an infusion into a vein. It gives the liver a working copy of the gene it needs to make the clotting protein factor IX.
Every report comes from a Lived member, sent anonymously.
Have you tried Hemgenix (Etranacogene Dezaparvovec) for Hemophilia B?
Etranacogene dezaparvovec, sold as Hemgenix, is a one-time gene therapy for adults with hemophilia B. In hemophilia B, an inherited change in the gene for clotting factor IX leaves the blood with too little of this protein. Bleeds last longer than they should and can start without an obvious injury, often inside joints and muscles. Many people with the more severe forms prevent bleeds with regular factor IX infusions into a vein, usually for life. Hemgenix is approved in the US for adults with hemophilia B who currently use factor IX prophylaxis (regular preventive infusions), who have had a life-threatening bleed now or in the past, or who have repeated serious bleeds that start on their own. Its safety and effectiveness in children have not been established, and it is not intended for women; the studies enrolled adult men. Staying on factor IX prophylaxis remains an option, and the decision is usually made with a specialist hemophilia team.
Factor IX is one of the proteins the liver makes so that blood can form a stable clot. Hemgenix uses a modified virus, called an adeno-associated virus type 5 (AAV5) vector, as a delivery vehicle. After the infusion, the vector travels to the liver and delivers a working copy of the factor IX gene into liver cells. Those cells then make factor IX themselves and release it into the blood, so the body has a steady supply instead of the short-lived boost that each factor IX infusion provides. The gene it carries is the Padua variant, a naturally occurring form of factor IX that is more active than the usual version, so each unit of protein does more clotting work.
Hemgenix is given once, as a single infusion into a vein in the arm at a specialist center. The dose is calculated from body weight, and the pharmacy prepares a kit for that person. The diluted product runs at a fixed rate, which takes about an hour for most people and longer for those weighing 120 kg (about 265 pounds) or more. Before treatment, blood tests check for factor IX inhibitors (antibodies that block factor IX) and for active hepatitis B or C. The liver is also assessed with blood tests, an ultrasound and elastography, a scan that measures liver stiffness as a sign of scarring. After the infusion, everyone forms antibodies against the AAV5 vector, so Hemgenix cannot be given a second time. Some people still need factor IX infusions during the first weeks while their own production builds up.
The most common effect is a rise in liver enzymes, especially ALT (alanine aminotransferase), a blood marker of irritated liver cells. In the main studies about 4 in 10 people had a raised ALT, usually without any symptoms and most often in the first few months. It matters because the rise can reflect the immune system reacting to the treated liver cells, which may lower the amount of factor IX they make. ALT is therefore checked weekly for 3 months and then monthly until a year after treatment. A rise may be treated with a tapering course of a corticosteroid such as prednisolone, which in the studies lasted a few months. Headache, flu-like symptoms, tiredness, feeling generally unwell and nausea were also reported, along with a rise in creatine kinase, a muscle enzyme seen on blood tests. About a third of people had a reaction during or soon after the infusion, such as chest tightness, lightheadedness, flushing, rash, chills or headache. Serious allergic reactions, including anaphylaxis, are possible. Staff watch for these throughout the infusion and for at least 3 hours afterward, and can slow or pause the infusion and give an antihistamine or steroid. Most reactions settled within a day, and the rest within about a week.
Hemgenix is not given to anyone who has, or has ever had, factor IX inhibitors. Treatment is postponed while hepatitis B or C is active, because active infection may make the therapy less effective or raise the risk of side effects. People with advanced liver scarring or severe kidney disease were not included in the studies, so how well it works for them is unknown. Some of the vector's DNA can become inserted into the DNA of liver cells, which in theory could contribute to liver cancer. No liver cancer caused by Hemgenix has been seen. One case occurred in a trial participant who had a history of hepatitis B, hepatitis C and alcohol use, and genetic testing suggested it was not likely related. People with risk factors for liver cancer are advised to have yearly liver ultrasounds and an alpha-fetoprotein (AFP) blood test, a tumor marker, for five years afterward. After the infusion, traces of the vector can appear in blood, semen and other body fluids for months or longer, and it is not known exactly how long this lasts. Recipients should not donate blood, organs, tissues or cells. Extra factor IX concentrate also affects factor IX test results, so the care team needs to know about every infusion used after treatment.
Factor IX made by the liver usually becomes measurable about three weeks after the infusion and builds over the following months. In the main study, participants started with factor IX levels of 2 percent of normal or lower. After treatment the average level was about 36 percent of normal and stayed steady through five years, though individual results ranged widely, from about 5 percent to about 75 percent. In that study, the yearly bleeding rate fell by 63 percent compared with the period on regular factor IX prophylaxis, and use of factor IX concentrate fell by 96 percent. About 6 in 10 participants had no bleeds at all in the year measured after the therapy took effect, and most stopped prophylaxis. A few did not respond well enough and went back to regular factor IX, including one person with very high preexisting antibodies to AAV5. Results beyond five years are not yet known. The first year involves frequent blood tests: weekly liver and factor IX checks for about 3 months, then monthly liver checks until the one-year mark, with follow-up continuing after that. If bleeding is not controlled, or bleeds start coming back, contact the hemophilia team promptly; they will check factor IX activity and test for inhibitors. Factor IX concentrate may still be needed to treat some bleeds.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Hemgenix (Etranacogene Dezaparvovec), what you've noticed, or ask the community a question.